새로 진단된 GBM의 치료를 위한 RT 및 TMZ와 병용되는 Optune®(종양 치료 분야)의 중추적, 무작위, 공개 라벨 연구 (EF-32)
EF-32: 새로 진단된 교모세포종 치료를 위한 방사선 요법 및 테모졸로마이드와 병용한 Optune®(종양 치료 분야, 200kHz)의 중추적, 무작위, 공개 라벨 연구
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Essen, 독일, 45147
- University Hospital Essen
-
Freiburg im Breisgau, 독일, 79106
- University Medical Center Freiburg
-
Leipzig, 독일, 04103
- University Hospital Leipzig
-
Munich, 독일, 81675
- Rechts der Isar Hospital
-
Tübingen, 독일, 72076
- University Hospital Tübingen
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, 미국, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, 미국, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, 미국, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, 미국, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, 미국, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, 미국, 91010
- City of Hope National Medical Center
-
Fullerton, California, 미국, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, 미국, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, 미국, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, 미국, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, 미국, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, 미국, 92868
- St. Joseph Hospital of Orange
-
Orange, California, 미국, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, 미국, 94303
- Stanford University Cancer Institute
-
San Diego, California, 미국, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, 미국, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, 미국, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, 미국, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, 미국, 32224
- Mayo Clinic
-
Jacksonville, Florida, 미국, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, 미국, 32804
- AdventHealth
-
Orlando, Florida, 미국, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, 미국, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, 미국, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, 미국, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Rush University Medical Center
-
Chicago, Illinois, 미국, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, 미국, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, 미국, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, 미국, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, 미국, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, 미국, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, 미국, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, 미국, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, 미국, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, 미국, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, 미국, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, 미국, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, 미국, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, 미국, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, 미국, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, 미국, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, 미국, 14642
- University of Rochester Medical Center
-
Syracuse, New York, 미국, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, 미국, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, 미국, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, 미국, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, 미국, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, 미국, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, 미국, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, 미국, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, 미국, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, 미국, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, 미국, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, 미국, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, 미국, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, 미국, 77030
- Houston Methodist Hospital
-
Houston, Texas, 미국, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, 미국, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, 미국, 98122
- Swedish Health Services
-
Seattle, Washington, 미국, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- West Virginia University Cancer Institute
-
-
-
-
-
Liège, 벨기에, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
-
Lausanne, 스위스, CH-1011
- Lausanne University Hospital
-
Zurich, 스위스, 8091
- University Hospital Zurich
-
-
-
-
-
Liverpool, 영국, L7 8YA
- Clatterbridge Cancer Centre
-
London, 영국, SE1 9RT
- Guy's Hospital
-
London, 영국, W6 8RF
- Charing Cross Hospital
-
Nottingham, 영국, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, 영국, PR29HT
- Royal Preston Hospital
-
-
-
-
Innsbruck
-
Innsbruck, Innsbruck, 오스트리아, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, 오스트리아, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, 오스트리아, 5020
- University Hospital Salzburg
-
-
-
-
-
Jerusalem, 이스라엘, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, 이스라엘, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, 이스라엘, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, 이스라엘, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, 이스라엘, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, 일본, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, 일본, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, 일본, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, 일본, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
Brno
-
Brno, Brno, 체코, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, 체코, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, 체코, 150 30
- Na Homolce Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, 캐나다, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, 캐나다
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, 캐나다
- Princess Margaret Cancer Centre
-
Toronto, Ontario, 캐나다
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, 캐나다
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
-
Angers, 프랑스, 49055
- Institut de cancérologie de l'Ouest
-
Bron, 프랑스, 69677
- Pierre Wertheimer Hospital
-
Marseille, 프랑스, 13305
- Hôpital la Timone
-
Nice, 프랑스, 06000
- University Hospital Nice
-
Paris, 프랑스, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, 프랑스, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, 프랑스, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, 프랑스, 94805
- Gustave Roussy Institute
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
활성 비교기: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression Free Survival (PFS)
기간: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
기간: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
기간: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
기간: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
기간: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
기간: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
기간: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
기간: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TRIDENT EF-32
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .